RESEARCH TRIANGLE PARK, N.C.– Quintiles today announced that it has been chosen as a preferred provider by Bristol-Myers Squibb Company (NYSE:BMY) to provide global support for Bristol-Myers Squibb's central lab work, biomarker testing and assay development for the next five years. "This agreement deepens the commitment our companies share to providing patients access to effective, safe and affordable treatments," said Thomas Wollman, Senior Vice President of Quintiles Global Laboratories. "We look forward to working with Bristol-Myers Squibb to bring personalized medicine into mainstream drug development."
Quintiles is the world's largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50, best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.
Mari Mansfield, Corporate Communication ([email protected])
Karl Deonanan, Investor Relations ([email protected])